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Background: A randomized, controlled trial, intended to include 460 patients, is currently studying peroperative
goal-directed hemodynamic treatment (GDHT) of aged hip-fracture patients. Interim efficacy analysis performed on
the first 100 patients was statistically uncertain; thus, the trial is continuing in accordance with the trial protocol.
This raised the present investigation’s main question: Is it reasonable to continue to fund the trial to decrease
uncertainty? To answer this question, a previously developed probabilistic cost-effectiveness model was used. That
model depicts (1) a choice between routine fluid treatment and GDHT, given uncertainty of current evidence and
(2) the monetary value of further data collection to decrease uncertainty. This monetary value, that is, the expected
value of perfect information (EVPI), could be used to compare future research costs. Thus, the primary aim of the
present investigation was to analyze EVPI of an ongoing trial with interim efficacy observed.
Methods: A previously developed probabilistic decision analytic cost-effectiveness model was employed to
compare the routine fluid treatment to GDHT. Results from the interim analysis, published trials, the meta-analysis,
and the registry data were used as model inputs. EVPI was predicted using (1) combined uncertainty of model
inputs; (2) threshold value of society’s willingness to pay for one, quality-adjusted life-year; and (3) estimated
number of future patients exposed to choice between GDHT and routine fluid treatment during the expected
lifetime of GDHT.
Results: If a decision to use GDHT were based on cost-effectiveness, then the decision would have a substantial
degree of uncertainty. Assuming a 5-year lifetime of GDHT in clinical practice, the number of patients who would
be subject to future decisions was 30,400. EVPI per patient would be €204 at a €20,000 threshold value of society’s
willingness to pay for one quality-adjusted life-year. Given a future population of 30,400 individuals, total EVPI
would be €6.19 million.
Conclusions: If future trial costs are below EVPI, further data collection is potentially cost-effective. When applying a
cost-effectiveness model, statements such as ‘further research is needed’ are replaced with ‘further research is cost-
effective and ‘further funding of a trial is justified’.
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Before conducting costly clinical trials, researchers may
need to estimate trial costs and convince funding bodies
that returns on investment are acceptable. Large clinical
trial protocols include an interim analysis plan, whose
objectives usually cover (1) safety, efficacy, or ethical is-
sues and (2) assessment of expected difficulties with pa-
tient enrolment that could influence the trial’s costs and
the credibility of its results. Interim analyses of efficacy
may or may not be conclusive, depending on the
detected effect size and the pre-trial sample size estima-
tion. However, interim analysis results may influence
investigators; consequently, standards for managing in-
terim results and for implementing various statistical
analysis methods have been recommended [1,2]. When
the primary outcome’s statistical uncertainty, as revealed
by interim analysis, indicates need for further data
collection, researchers may ask the question: Is it rea-
sonable to continue to fund the trial to decrease uncer-
tainty? Increasingly, resource allocation in health care
considers the principles of cost-effectiveness in different
jurisdictions; cost-effectiveness has become a key criterion
for decision makers when deciding which health-care in-
terventions should be made available in collectively
funded health-care systems [3]. Because the purpose of a
clinical trial is to reach a decision [4], the principles of
cost-effectiveness and value for money could be, and per-
haps should be, applied to decide, after the interim ana-
lysis, if a clinical trial should be extended. The question
then becomes whether current data from the interim ana-
lysis are sufficient or whether data collection should con-
tinue to decrease uncertainty regarding treatment choices.
Further, when deciding whether or not to introduce a new
technology, it is recommended that such a decision be
made by considering the cost-effectiveness of the technol-
ogy, taking into account all existing evidence and whether
additional research is itself efficient. Thus, there is suffi-
cient evidence regarding the cost-effectiveness of an inter-
vention when the costs of undertaking additional research
are greater than the benefits of reducing uncertainty [3].
Extending this rationale to clinical trials, after interim ana-
lysis, a trial should be continued when the costs of under-
taking additional research are less than its benefits, in
terms of reducing uncertainty. This article describes
such an interim analysis of a randomized controlled clin-
ical trial of aged hip-fracture patients (ClinicalTrials.gov
NCT01141894) and the estimation of the value of
extending the trial on the basis of value of information
analysis. The trial’s objective was to compare costs and
consequences of routine peroperative fluid treatment with
goal-directed hemodynamic treatment (GDHT). The in-
terim analysis during the trial determined that, due to stat-
istical uncertainty, further data collection was required.
Thus our present investigation’s primary and secondaryaims were to (1) analyze expected value of perfect infor-
mation (EVPI) when studying GDHT, and (2) provide
decision support material when stakeholders must deter-
mine if it is reasonable to fund further data collection after
the interim analysis.
Our investigation modeled cost-effectiveness and esti-
mated result uncertainty of the clinical trial. Our model
depicted (1) the choice between treatment options, given
current, best available evidence; and (2) the monetary
value of a decision to collect further information, via fu-
ture clinical research, to decrease uncertainty. Here,
monetary value is expressed as a concept called expected
value of perfect information (EVPI) [5,6].
Methods
This section describes (1) the clinical trial’s design and
efficacy data extracted from the interim analysis, (2) the
decision-analytic model and model inputs used in our
analyses, and (3) the EVPI estimation method.
Design of the clinical trial, interim analysis efficacy data
Our data source was a single-centre, open, randomized
(1:1), and controlled, parallel-group, superiority clinical
trial. The trial is on-going at a primary teaching hospital,
Karolinska University Hospital, Huddinge, Sweden. Eli-
gible patients (aged ≥ 70 years, weight ≥ 40 kg) are those
scheduled for hip-fracture surgery during regular operat-
ing hours. Patients were enrolled if a signed informed
consent was obtained after they received information
about trial-specific procedures. The local research ethics
committee approved the trial (ID: 2008–1240–31), and
Sweden’s Medical Products Agency authorised the trial
(MPA ID; 151:2009/81083).
Trial objectives
Primary: to identify the absolute and relative risk of
post-operative complications at hospital discharge. Sec-
ondary: to analyze cost-effectiveness of GDHT compared
with routine fluid treatment.
Statistics
Using expected absolute risk (0.61) [7] and relative risk
(0.63) [8] for post-operative morbidity (GDHT compared
with routine fluid treatment), a sample size calculation
was made (80% power, the type I error <0.05). Assuming
that 57% of complications could be reduced due to pa-
tients’ age and comorbidity [9], a 460-patient sample size
is required. For the analysis Statistical software was used
(version 10. StatSoft Inc, Tulsa, OK, USA).
Interventions
Interventions included the following: (1) GDHT to attain
oxygen delivery index >600 mL/ min-1 m-2 (using fluids
and dobutamine) and (2) a protocol-guided routine fluid
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LiDCO™ monitor ( LiDCO Ltd., Sawston, Cambridge,
United Kingdom).
The effect size per interim analysis
This article reports relative risk of post-operative com-
plications from the trial because these data were speci-
fied in the interim analysis strategy. See Figure 1 for the
inclusion sequence and Table 1 for patient characteris-
tics. The post-operative outcome is expressed by relative
risk (95% confidence intervals) taken from an intention-
to-treat analysis. In-hospital mortality (n = 3) contrib-
uted to post-operative complications.
The model and model inputs used in this investigation
A decision-analytic probabilistic cost-effectiveness model
(Figure 2) was developed. The model illustrates the con-
sequences of use of GDHT or routine fluid treatment
for a hypothetical cohort of patients after hip fracture dur-
ing 5 post-operative years [10]. Model inputs consisted of
these estimates: (1) probability of post-operative morbidity
and mortality, (2) health-related quality of life, and (3)
costs. Model outputs consisted of (1) aggregated health-
care costs and (2) quality-adjusted life-years (QALYs). The
model was programmed and analyzed using Microsoft
Excel (2007, version 12.0.6425.1000). The analysis applied
Swedish hospital costs that were converted to euros using
the exchange rate of €1 = SEK 9.41. Costs and QALYs
were discounted by 3% annually.
More comprehensive descriptions of the model struc-
ture and data used for model parameters are available
elsewhere [10] (Additional files 1 and 2). The modelFigure 1 Inclusion sequence of the first 100 randomized
patients in the trial: ClinicalTrials.gov NCT01141894.contained two parts: a decision tree, used to estimate
short-term costs and effects, and a Markov structure,
used to estimate long-term costs and effectsThe
decision-tree in Figure 2A illustrates short-term out-
come for hypothetical patients. The tree starts with the
decision (rectangle) between the two alternatives,
followed by the chance node (circle), whereby the
patients can transition (by chance) along the arrows to
selected, post-operative outcomes (triangles). These out-
comes are as follows: uncomplicated recovery; cardiovas-
cular complications; stroke; other complications (that is,
pulmonary or urinary tract infections, post-operative
confusion, kidney insufficiency, wound infections, and
pulmonary embolism); or death.
Model inputs in the decision tree
The model inputs in the decision tree (Table 2)
consisted of (1) probability estimates of the post-
operative outcome, (2) estimates of the post-operative
health state (expressed by QALY weights), and (3) costs.
Probability estimates for routine fluid treatment, by
type of post-operative complication, could not be calcu-
lated from the interim data due to the low number of
observations per complication (n <5). Instead, these esti-
mates were extracted from a Swedish patient cohort
with hip fracture.[7] For GDHT, the estimate of relative
risk from the interim analysis was applied to the prob-
ability estimates for the routine fluid treatment by type
of post-operative outcome (Table 2). Mortality estimates
could not be calculated from the interim data due to the
low number of observations (n <5); instead, published
meta-analysis data were used [8].
Pre-fracture QALY weights were obtained from an
age-matched general population [11] (aged >80 years).
Post-fracture QALY weights associated to the selected
post-operative outcomes were unavailable, so QALY
weights were obtained from a representative sample with
the disease in the population [11,12] and from a longitu-
dinal Swedish clinical trial [13].
The long-term model (Markov structure) extrapolated
the effects of the post-operative outcome to post-
operative health conditions and the influence of the out-
come on long-term survival (Figure 2B). Hypothetical
patients transitioned among these health conditions or
stayed in the current condition during the cycles in 1
year (thatis, a Markov cycle). Recovery is allowed from
the ‘other complications’ state; we assumed that patients
continued to live with cardiovascular complications or
stroke after the initial event. During each Markov cycle,
quality of life and number of survivors decrease.
Model inputs in the Markov structure
Model inputs in the long-term model (Table 2) consisted
of survival data, QALY weights, and cost data.
Table 1 Patient characteristics and interim efficacy data; values are absolute or mean ± SD
Patient characteristics GDHT Routine fluid treatment
Number allocated 49 50
Age, years (mean) 86 (± 7) 85 ( ± 7)
Sex, male/female 13/36 9/41
American Society of Anesthesiologists’ grading (1/2/3/4) 0/13/31/5 1/15/29/5
Number of patients with complications (including in-hospital mortality) 15 19
Relative risk of GDHT compared to routine fluid treatment based on intention to treat (95% CI) 0.806 (0.464 to 1.397)
CI confidence interval, GDHT goal-directed hemodynamic therapy.
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ard mortality was used. For patients with complications,
disease-related mortality was used (non-fractured patients
with cardiovascular, cerebrovascular or with other diseases).
In instances of cardiovascular complications or stroke,
survival was estimated using age- and disease-related
mortality from the Swedish National Stroke Registry
[14] and the Swedish National Registry on Secondary
Prevention in Cardiac Intensive Care (Kalle Spångberg,
Ph.D., section manager, Uppsala Clinical Research Center,
Uppsala University, Uppsala, Sweden, written communi-
cation: 15 May 2009).
QALY weights associated with short-term clinical out-
comes were allocated in the early simulation in the Markov
structure. The post-fracture QALY weights were multiplied
by the time spent in the current state of health, which
resulted in the number of QALYs.Figure 2 Cost-effectiveness model. A) Short-term model, the decision tr
towards the selected post-operative outcomes (triangles). These transitions
health-related quality-of-life weights. For the routine fluid treatment, proba
Hospital [7]. * For goal-directed hemodynamic treatment (GDHT), the interi
patients were used [8]. B) The long-term model, Markov structure. The hyp
health-related quality-of-life weights. During annual cycles of simulation, th
These transitions are characterized by probability estimates (p11 to p21). {A
costs are aggregated.Mean costs of inpatient and outpatient long-term med-
ical care services were obtained from the Epidemiological
Centre of the Swedish National Board of Health and
Welfare for patients undergoing surgery for hip fracture
in 2007 and hospitalized during 2008 (Leif Forsberg,
statistician, Department of Statistics, Monitoring and
Evaluation, Swedish National Board of Health, Stockholm,
Sweden, written communication: 7 December 2009).
Hospital costs for each post-operative complication were
acquired from individual patient-specific cost data obtained
from University Hospital in Lund, Sweden.
Assumptions in the model
The following assumptions were made in the model:
1. Hypothetical patients could have one post-operative
complication.ee. The arrows represent the transition of the hypothetical patients
are characterized by probability estimates (p1 to p10), costs, and
bility estimates were extracted from a cohort from Lund University
m analysis was used. ** For mortality, published data on high-risk
othetical patients were allocated to health states characterized by
e patients transition in the model or stay in the same heath state.
U After each cycle, quality-adjusted life-years and direct health-care
Table 2 Model inputs
Model inputs Estimates Distributions
Short-term clinical outcome (routine care)a
Probability of…















Mortality associated with cardiovascular
diseaseb
First year 0.107 Deterministic
Second year 0.058 Deterministic
Third year 0.056 Deterministic
Mortality associated with stroke at 3
monthsc
0.15 Deterministic
Mortality associated with other
complicationsa
0.18 Beta (31; 140)
Recovery associated with other
complicationsa
0.41 Beta (70; 101)
Mortality after recovery with other
complicationsa
0.15 Beta (17; 95)
Costs/patient for routine fluid treatment
in the clinical routine (€)d
Medical device for fluid treatment 11 Deterministic
Human resources in pre-operative
area
27 Deterministic
Human resources during anesthesia 117 Deterministic
Costs/patient for GDHT (€)d
Medical device for GDHT 221 Deterministic
Human resources in pre-operative area 159 Deterministic
Human resources during anesthesia 401 Deterministic
Post-operative direct health-care costs/
patient (€)e
Cardiovascular complications
Myocardial infarction 7,498 Gamma (90; 83)
Heart failure 9,903 Gamma (104;95)
Stroke 7,550 Gamma (8; 956)
Other complications
Pneumonia 8,514 Gamma (106; 81)
Renal failure 12,197 Gamma (6; 1442)
Wound infection 8,566 Gamma (218; 39)
Deep-vein thrombosis 7,617 Gamma (62; 124)
Pulmonary embolism 10,190 Gamma (17, 600)
Table 2 Model inputs (Continued)
Gastrointestinal bleeding 9,900 Gamma (64, 154)
Confusion 7,961 Gamma (866; 9)
Death 9,020 Gamma (273, 33)
No complications 6,753 Gamma (956; 7)
Direct health-care costs, first year after
hospital stay (€)f
State after…
No complications 147 Deterministic
Cardiovascular complications 7,673 Deterministic
Stroke 7,512 Deterministic
Other complications 7,314 Deterministic
Recovery from other complications 396 Deterministic
Death 4,837 Deterministic
Direct health-care costs, 2 to 10 year
after hospital stay (€)f
State after…
Cardiovascular complications 386 Deterministic
Stroke 402 Deterministic
Other complications 396 Deterministic
QALY weights, estimates [7]
>80 years age 0.74 Beta (322; 113)
Recovered after other
complication [9]
0.66 Beta (227; 117)
Decrements of QALY weights [8]
State after…
Cardiovascular complications −0.19 Gamma (298;
0.0006)
Stroke −0.35 Gamma (100;
0.0035)
Other complications −0.15 Gamma (100;
0.0007)
GDHT goal-directed hemodynamic therapy, QALY quality-adjusted life years,
€ Euros.
I The Dirichlet distribution is a multivariate normalization of beta distribution
that considers that the sum of probabilities is 1.0.
a Swedish Registry on Hip Fracture.
b Swedish National Registry on Secondary Prevention in Cardiac
Intensive Care.
c Swedish National Stroke Registry.
d Karolinska University Hospital in Huddinge, Sweden.
e University Hospital in Lund, Sweden.
f Epidemiological Centre of the Swedish National Board of Health.
Probability estimates characterized each post-operative outcome
(the post-operative complications as well as death).
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of quality of life during the 5 post-operative years
equal to that of patients in the non-fractured
population who had cardiovascular complications or
stroke.
3. The 5-year survival rate after uncomplicated
recovery for patients with hip fracture was the
same as that for aged non-fractured patients
(standard mortality).
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cardiovascular complications and stroke in patients
with hip fracture was the same as that in non-
fractured patients with cardiovascular complications.
Probabilistic sensitivity analysis
To incorporate the uncertainty of model parameters in
the probabilistic sensitivity analysis, each parameter as-
sociated with statistical uncertainty was defined with
probability distributions. The choice of distributions was
guided by recent recommendations by Briggs et al. [6]
and was parameterized with the mean and standard
error. The values of QALY weights are constrained on
the interval 0 to 1 and for these beta distributions were
used. The transition probabilities are mutually exclusive
events (multinomial data) and for these Dirichlet distri-
bution was used that is a multivariate generalization of
beta distribution. The skewed cost data and the decre-
ments of QALY weights constrained on the interval 0 to
positive infinity, and for these parameters gamma distribu-
tion was used. The relative risk (ratio) was transformed
into a log form and log-normal distributions were used. In
Table 2 the distributions used are listed for each param-
eter. The long-term costs were based on fixed price lists,
and the survival rates after cardiovascular complications
or stroke were extracted from registries on large popula-
tions with low standard error (Table 2). Thus, both these
sets of parameters were incorporated as deterministic
probabilities in the model.
To propagate the uncertainty of the parameters
through to the cost-effectiveness estimate, a second-
order Monte Carlo simulation was used; the cohort was
simulated through 5 Markov cycles (years). The input
parameters were sampled using the distributions given
in Table 2. In each simulation, the set of model inputFigure 3 Incremental costs and effects (ΔQALY) of goal-directed hemo
dotted line represents one threshold value of how much society would be
in the target population.values was randomly drawn from the model parameter’s
defined probability distributions. The simulation then
was performed 1,000 times [6], generating 1,000 estimates
of aggregated costs and QALYs. In Figure 3, incremental
costs (ΔC = CostGDHT - CostRoutine) are plotted against
incremental effects (ΔE = EffectGDHT - EffectRoutine).
For 91.5% of simulations, GDHT (compared with routine
fluid treatment) was better and less costly (ΔE positive
and ΔC negative) or was better and more costly (both ΔE
and ΔC positive).
Expected value of perfect information estimation method
As shown in Figure 3, the model propagated parameter
uncertainty onto the uncertainty of cost-effectiveness. If
a decision was to be made regarding adoption of
GDHTon the basis of expected costs and QALYs from
the current evidence, this decision would be associated
with uncertainty and there would be a risk of making an
incorrect decision. In Figure 3, the number of values in
upper-left quadrant (GDHT more costly and less effect-
ive) contributes to the probability of making such a
decsion. In addition, some values in the upper-right
quadrant also may represent an incorrect decision -
despite GDHT resulting in positive incremental effect
(ΔE) - because the cost per QALY may be perceived as
being too high. The primary decision-making factor in
this quadrant is a threshold value of how much society
is willing to pay for 1 additional life-year with full health
in the target population. The slope of the dotted line (λ)
on Figure 3 illustrates a value of €20,000 per QALY. The
line represents one possible threshold value (or cost-
effectiveness threshold); values above the dotted line
represent an incorrect decision.
The combination of uncertainty of model inputs and
society`s willingness to pay for 1 additional life-yeardynamic treatment (GDHT) versus routine fluid therapy. The
willing to pay for 1 additional life-year with full health for each patient
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of making an incorrect decision are quantified, given the
uncertainty of model inputs and the consequences of the
relinquished or foregone benefit if GDHT were adopted.
The purpose of further data collection is to eliminate
risk of relinquished benefit. In practice, the value of
this relinquished benefit is the EVPI, whereby a deci-
sion is made for one future patient. The EVPI must be
calculated for all potential future clinical decisions on
all future patients who will gain by the advantage of
additional research during the treatment’s (for example,
GDHT) expected lifetime in clinical use. Therefore, the
effective population, that is, the population that may
benefit in the future during the treatment’s lifetime, is
estimated (and the discount rate is applied). The total
EVPI population is calculated by multiplying the EVPI
per patient by the population that might benefit in the
future (effective population):
PopulationEVPI ¼ EVPIpatient  effectivepopulation
Results
Figure 3 illustrates the model outputs: expected costs
and effects. It shows that in 76.2% of the simulations,
the GDHT is less costly and more effective (negative
incremental cost, positive incremental effect); in 17.1%
of simulations, GDHT is more costly and more effective
(positive incremental cost and positive incremental effect);
and in 6.7% of simulations, GDHT more expensive and
less effective (positive incremental cost and negative
incremental effect).Figure 4 The expected value of further information for the Swedish p
value of perfect information (EVPI) is plotted against the willingness to payExpected value of perfect information
At a cost-effectiveness threshold (λ) of €50,000, the EVPI
is €337 per patient. At a threshold of €20,000, the EVPI
per patient is €204. Given 6,440 operations annually in
Sweden (for patients aged >80 years), a conservative
expected lifetime of 5 years for the GDHT technology,
and a 3% discount per year, the EVPI for the effective
population (30,378 individuals) is €6.19 million to €10.2
million when the cost-effectiveness threshold is between
€20,000 and €50,000. (The authors assumed that new
technologies or other innovations may influence clinical
practice and that GDHT may not be the current trend
after 5 years.) The model was run using varying values
of a cost-effectiveness threshold, which generated vary-
ing expected values of perfect information (Figure 4).
Discussion
After classical statistical inference analysis of the interim
efficacy data, our model showed that the GDHT should
not be adopted in the clinical routine because the null
hypothesis (relative risk = 1.0) was within limits of the
95% confidence interval (Table 1). However, the cost-
effectiveness analysis and its accompanying probabilistic
sensitivity analysis, taking existing evidence into account,
showed that, in 93.3% of the simulations, treating pa-
tients with GDHT, when compared to routine fluid
treatment, resulted in QALYs gained (Figure 3). How-
ever, if a decision was made on the basis of current in-
formation, some iteration found that the decision could
be incorrect where there are higher health-care costs
and less effect (upper-left quadrant on Figure 3) or when
costs are above the cost-effectiveness threshold (upper-
right quadrant). The EVPI is the value of the incorrectatient population aged >80 years with hip fracture. The expected
per quality-adjusted life-year (cost-effectiveness threshold).
Bartha et al. Trials 2013, 14:205 Page 8 of 10
http://www.trialsjournal.com/content/14/1/205decision as it is the maximum acceptable value that soci-
ety should pay to eliminate decision uncertainty via fur-
ther data collection. The cost-effectiveness is a related
value that society is willing to pay for 1 additional life-
year with full health (cost-effectiveness threshold, λ) for
each patient in the population of interest. In Sweden,
there is no fixed officially accepted threshold or range,
but a cost-effectiveness threshold of between €20,000
and €50,000 has been discussed in this paper; in excep-
tional cases, this threshold can be even higher. Severity
of the health condition under consideration is the major
reason for accepting varying thresholds [15-20]. With a
broad range of alternative implicit thresholds for society’s
willingness to pay for one QALY, we chose a conservative
interpretation in drawing our conclusions. For the broad
range of cost effectiveness thresholds used in this analysis,
we found that the EVPI is in the interval of €6.19 to
€10.2 million.
The rationale of probabilistic modeling
The rationale of probabilistic modeling is to reflect the
uncertainty of the model inputs and to describe the un-
certainty about the model outputs. In non-linear models,
the model outputs are the result of multiplicative or
power functions. The interest of a decision-maker is the
expected distribution of model outputs. This cannot be
obtained by analyzing the upper-limit and lower-limit
95% confidence intervals of the model inputs [21]. In-
stead, the uncertainty of model outputs is obtained by
probabilistic sensitivity analyses [21]. The uncertainty of
model outputs implies the possibility of an incorrect deci-
sion that results in costs (forgone benefits). In the decision
theoretic approach, a value is ascribed to the reduction of
uncertainty (creation of additional information) and a deci-
sion may include the option to acquire additional informa-
tion. It is important to note that the current calculated
EVPI is conditional on model uncertainty due to the
assumptions made (and listed in the methods) about the
model structure and the data used. Such assumptions are
not accounted for in the distributions of the parameters
because they originate from active choices made rather
than from statistical uncertainty. The effect of our four
assumptions on mean cost-effectiveness and its uncertainty
was investigated in the previously published model [10]
and was found to have a marginal influence on the results.
Thus, our assumptions have not been investigated here
with regard to their influence on EVPI.
The rationale of the expected value of perfect
information
EVPI implies that data are obtained from an infinite
sample that removes all uncertainty and places an upper
limit of the value of further research, given that add-
itional data may reduce uncertainty. In reality, the valueof further data collection resulting in new information is
most likely far less. Further research may yield partial in-
formation on the parameters of interest (not an infinite
sample). The value of new information thus depends on
the uncertainty of the new parameter estimates. With
perfect information, a decision-maker would know how
the uncertainties would resolve and could make the cor-
rect decision. The better decision would be to choose a
treatment with better effect at costs below a threshold
value of what the society is willing to pay per gained
QALY. EVPI can help decision makers identify which re-
search is potentially cost-effective and which is not. It
does not imply that research can be continued until the
costs of research are below the EVPI.
Publications regarding the EVPI method for interim
analysis appear to be non-existent. In a broader perspec-
tive, however, EVPI was recently used for two pilot stud-
ies of research priorities in the United Kingdom [22-25].
In our study, we conclude that trial NCT01141894
should be continued, given the uncertain interim efficacy
data and the rules of classical statistical inference. How-
ever, recruitment time in this on-going trial has been
prolonged for logistical reasons (almost 30% of the
hip-facture surgeries initially planned during regular
operating room hours were performed during off hours
(65 out of 187 assessed for eligibility; see Figure 1).
This factor increases trial cost; therefore, it is reason-
able to address the monetary value of further research
because it is not obvious that the trial should be fi-
nanced for further data collection, given scarce clinical
research resources.
Interim analysis risks
Sharing results of interim analyses could influence an
on-going trial, and guidelines request that results from
an interim analysis not be made public [1,2,26]. This is
important because further recruitment could be affected
and because patients could prefer any of the treatments,
as seen in the preliminary analysis of efficacy and ad-
verse events (although the intervention is not yet scien-
tifically proven). In addition, the risk of introducing bias
into the on-going trial could be substantial [26]. In line
with the current recommendations, an interim analysis
and the subsequent decision on further data collection
should be performed by confidential data safety and
monitoring committees. While an EVPI analysis could
support such a decision or be used as an argument when
applying for further funds, guidelines nevertheless sug-
gest that the results of an interim analysis in such in-
stances not be made public. However, the adherence to
these guidelines has been questioned in the past, and the
guidelines have been characterized as paternalistic [27].
Researchers in favor of making interim analyses public
believe that it is important to inform society, patients,
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trials in considering safety issues and sample size. How-
ever, it is important to note that current guidelines and
statistical methods insist on a blind interim analysis
[2,28]. The current trial was randomized but open and
blinded during analysis.
Conclusions
After analysis of interim efficacy data, further data collec-
tion in trial NCT01141894 is needed for statistical inference
analysis. A further 4 years of recruitment is planned, with a
12-month follow-up period. Even if predicted trial costs
increase, it seems reasonable to fund the trial further,
provided these costs remain below €6.19 million.
Decisions on funding clinical trials usually do not utilize
the results of health economic evaluations of the trials’ in-
terim analyses, even if the trials are very resource intensive
and are funded by public resources. With use of the
analytic framework, such as cost-effectiveness models,
we can replace the statement ‘further research is needed’
with ‘further research is cost-effective’ and ‘further funding
of a trial is justified.’
Additional files
Additional file 1: A decision tree starts with the decision (rectangle)
between the two alternatives followed by a circle (a chance node)
where alternative events are possible; these are illustrated by
branches coming out from the chance node, representing the
clinical pathways. The branches end with triangles representing
outcomes. The pathways are mutually exclusive and are characterized by
the probabilities; the sum of probabilities following each node is 1.0.
Each pathway is associated with health care costs and an outcome
(QALY). The expected costs and effects are based on the summation of
pathway values weighted by the pathway probabilities.
Additional file 2: The calculated probabilities of survival and
mortality following the post-operative complications are illustrated
for the routine fluid for five years. Each arrow represents a pathway
and the pathways are characterized with probabilities. Each pathway
is associated with costs and quality of life weights. The costs and quality
of life weights of each pathway are weighted by the corresponding
pathway probabilities. The sum of these weighted costs yields the
expected cost during the first year and the weighted quality of life index
multiplied by one year yields the expected quality adjusted life year
(QALY). The cycles are repeated five times and the aggregated costs and
QALYs are calculated. The same calculation is done for the GDHT.
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